All In Biotech

Drug Trial Radar · NCT04215653

A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers.

Last checked: Nov 19, 2026Latest source record: Jan 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 448 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

448

Planned (sponsor's estimate)

Start

Jan 20, 2020

Primary completion

Feb 15, 2021

Study completion Feb 28, 2021

Sponsor

Sponsor type
Industry
First posted
Jan 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3,double-blinded, double dummy, parallel, non-inferiority, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD compared with rabeprazole 10mg QD in patients with duodenal ulcers.

Conditions

  • Duodenal Ulcer,DU

Interventions

  • Anaprazole SodiumDrug

    administered orally once every 30-60 minutes before breakfast for 4 weeks

  • RabeprazoleDrug

    administered orally once every 30-60 minutes before breakfast for 4 weeks

  • Rabeprazole PlaceboDrug

    administered orally once every 30-60 minutes before breakfast for 4 weeks

  • Anaprazole Sodium PlaceboDrug

    administered orally once every 30-60 minutes before breakfast for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The endoscopic healing rate of duodenal ulcers at week 4, evaluated by blinded independency central reading.Time frame: Treatment of 4 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.